The hazard of accelerated tumor clonogen repopulation during radiotherapy
- PMID: 3390344
- DOI: 10.3109/02841868809090333
The hazard of accelerated tumor clonogen repopulation during radiotherapy
Abstract
When analysis of results of radiotherapy for nearly 500 patients with oropharyngeal cancer showed evidence for rapid tumor regrowth during extensions of treatment from about 5 weeks to about 8 weeks, we searched the literature on radiotherapy for head and neck cancer to determine whether it revealed similar evidence of accelerated tumor regrowth. Estimates of doses to achieve local control in 50% of cases (TCD50) were made from published local control rates, and the dependence of these doses on overall treatment duration was evaluated. In parallel, published scattergrams were analyzed to estimate the rate of tumor regrowth over the period of 4-10 weeks from initiation of therapy. Both analyses suggested that, on average, clonogen repopulation in squamous cell carcinomas of the head and neck accelerates only after a lag period of the order of 4 +/- 1 weeks after initiation of radiotherapy and that a dose increment of about 0.6 Gy per day is required to compensate for this repopulation. Such a dose increment is consistent with a 4-day clonogen doubling rate, compared with a median of about 60 days in published reports of unperturbed tumor growth rates. The values presented here are average values for a large number of patients: it is necessary, not only to verify the results of these retrospective analyses in prospective studies, but also to develop methods to predict the time of onset and rate of accelerated tumor clonogen repopulation in the individual patient.
Similar articles
-
Dose fractionation and tumour repopulation in radiotherapy for bladder cancer.Radiother Oncol. 1991 Jul;21(3):163-70. doi: 10.1016/0167-8140(91)90033-d. Radiother Oncol. 1991. PMID: 1924851 Review.
-
Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours.Radiother Oncol. 1994 Sep;32(3):197-200. doi: 10.1016/0167-8140(94)90018-3. Radiother Oncol. 1994. PMID: 7816938
-
Accelerated repopulation: friend or foe? Exploiting changes in tumor growth characteristics to improve the "efficiency" of radiotherapy.Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1377-83. doi: 10.1016/0360-3016(91)90301-j. Int J Radiat Oncol Biol Phys. 1991. PMID: 1938539
-
Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation.Radiother Oncol. 1990 Feb;17(2):95-102. doi: 10.1016/0167-8140(90)90096-f. Radiother Oncol. 1990. PMID: 2320748
-
Cell repopulation and overall treatment time.Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1071-5. doi: 10.1016/0360-3016(90)90036-j. Int J Radiat Oncol Biol Phys. 1990. PMID: 2211245 Review.
Cited by
-
Clinical results of external beam radiotherapy alone with a concomitant boost program or with conventional fractionation for cervical cancer patients who did not receive intracavitary brachytherapy.J Radiat Res. 2012 Nov 1;53(6):900-5. doi: 10.1093/jrr/rrs051. Epub 2012 Aug 1. J Radiat Res. 2012. PMID: 22859563 Free PMC article. Clinical Trial.
-
Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.Br J Radiol. 2013 May;86(1025):20130015. doi: 10.1259/bjr.20130015. Epub 2013 Mar 11. Br J Radiol. 2013. PMID: 23479396 Free PMC article.
-
Systematic analysis of RBE and related quantities using a database of cell survival experiments with ion beam irradiation.J Radiat Res. 2013 May;54(3):494-514. doi: 10.1093/jrr/rrs114. Epub 2012 Dec 23. J Radiat Res. 2013. PMID: 23266948 Free PMC article.
-
Continuous, hyperfractionated, accelerated radiotherapy (CHART).Br J Cancer. 1989 Mar;59(3):325-6. doi: 10.1038/bjc.1989.64. Br J Cancer. 1989. PMID: 2649133 Free PMC article. Review. No abstract available.
-
Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.Int J Clin Oncol. 2023 Apr;28(4):550-564. doi: 10.1007/s10147-023-02299-w. Epub 2023 Feb 3. Int J Clin Oncol. 2023. PMID: 36735115
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical